Related Experiment Video
Updated: Feb 19, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.1K
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies
Stefan Kiesgen1, Leonardo Chicaybam1, Navin K Chintala1
1Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Summary
Chimeric antigen receptor (CAR) T-cell therapy shows promise for solid tumors beyond blood cancers. This review covers advances, targets, and challenges for thoracic malignancies like lung cancer.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T cells are engineered immune cells targeting cancer antigens.
- Success in leukemia/lymphoma drives exploration in solid tumors.
Purpose of the Study:
- Review CAR T-cell therapy evolution for thoracic malignancies.
- Summarize targets and strategies for lung, mesothelioma, and esophageal cancers.
- Discuss barriers and solutions for solid tumor CAR T-cell therapy.
Main Methods:
- Literature review of adoptive T-cell therapy.
- Analysis of clinical trials for CAR T-cell therapy in thoracic cancers.
- Discussion of challenges and proposed strategies for solid tumor application.
Main Results:
- CAR T-cell therapy has advanced significantly for thoracic malignancies.
- Various targets are under investigation for lung, mesothelioma, and esophageal cancers.
- Key barriers include tumor microenvironment and target specificity.
Conclusions:
- CAR T-cell therapy holds potential for thoracic solid tumors.
- Overcoming current hurdles is crucial for clinical translation.
- Ongoing research focuses on optimizing CAR T-cell efficacy and safety.
